Answers are grounded in this paper and cite their sources.
Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was greater with ruxolitinib. (Funded by Novartis and Incyte; REACH3 ClinicalTrials.gov number, NCT03112603.).
No takes yet. Share an insight, caveat, or question.
Zeiser et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: